FAQs

Please ask if they would like to become part of our esteemed panel of clinicians. They can contact us to get started or feel free to forward their contact information to our Physician Liaisons at info@simplemd.com.

No, the program commonly follows the protocols described in the New England Journal of Medicine publications on GLP1 medications. Once off the medications, patients have reported long-term persistent benefits.

There are few negative side effects. However, every medication may have unintended effects. For that reason, we thoroughly review the risks and benefits for each individual patient to ensure the highest likelihood of success.

Individual results vary, but patients tend to lose between one to five pounds each week. The New England Journal of Medicine reported around 20% of patients starting weight but individual variances may exist.

We typically treat men and women looking to lose ten pounds or more and most have failed other programs in the past. Our patients range in age from teenagers to octogenarians.

Yes, our comprehensive program is not a diet; it’s a way of life. We empower you to transform your habits to lose weight and maintain a healthy lifestyle. Our programs are flexible enough to address your unique challenges and circumstances.

GLP-1 receptor agonists, are a type of medication that was initially approved by the FDA in 2005 to treat diabetes. However, over the years, these medications have been observed to provide additional benefits, such as weight loss and cardiovascular health improvement.

Among these medications, Novo Nordisk has developed two versions, Ozempic® and Wegovy® (both using base compound called semaglutide) with strong links to weight loss. As it stands, Wegovy® is the only GLP-1 medication with FDA approval specifically for weight loss. If you have a Body Mass Index (BMI) greater than 27 with an associated risk factor, or a BMI over 30, without contraindications, Wegovy® is often the primary choice, showing many patients losing 20% of their initial starting weight (more than any of its predecessors to date). 

Interestingly, a new GLP-1 receptor agonist named Mounjaro® (tirzepatide) has shown even more impressive results in a recent study published in the New England Journal of Medicine. The study reported a weight loss of about 25% of initial body weight in patients. Although Mounjaro® is currently approved for diabetes treatment, it is under final review for approval for weight loss treatment in non-diabetic, overweight patients. Many doctors have begun prescribing Mounjaro® off-label for weight loss, which is a common and legal practice when scientific evidence supports the medication's efficacy and safety for a non-FDA-approved use.

Due to the high demand for Ozempic, Wegovy, and Mounjaro, a worldwide shortage occurred, leading compound pharmacies to create their versions of semaglutide and tirzepatide. These pharmacies are not FDA-approved, but they are able to make medications for patients when standard options are not readily available. As the shortage increased, these compounded versions became widely available. Doctors can prescribe these compounded medications when standard options don't meet patients' needs, provided that patients understand the potential risks associated with compounded medications and then give their informed consent.

SimpleMD® does not endorse or have any financial affiliation with any pharmacy or entities that manufacture medications. SimpleMD’s role is to help coordinate the team of clinicians, pharmacists, insurers and health coaches that are often necessary to optimize a patients medical weight loss journey. 

We are so confident in your results, we offer a 100% money-back guarantee if you are not satisfied with the results that you achieve within the first 30 days following your purchase. Of course this covers 100% of the Membership Fee but does not include the cost of any medications prescribed for patients that is clearly disclosed to each patient in advance.